Sintx Technologies update strategic focus to medical device commercialization

SINTX Technologies (SINT) provided a comprehensive update on its operational progress, strategic initiatives, and financial position for the first quarter ended March 31.. SINTX has accelerated its transition from a diversified industrial-ceramics business to a pure-play medical device innovator. Silicon nitride’s proven biocompatibility, antimicrobial properties, and pro-regenerative properties uniquely position it for:Orthopedic implants; Spinal fusion devices; Dental products; Medical Textiles including: wound care, surgical masks, sutures, drapes and other antipathogenic surfaces. This strategic redirection aims to address large, underserved clinical needs where infection resistance and osteogenesis and tissue healing are critical. Recent scientific and commercial initiatives include:New R&D programs targeting implantable and antipathogenic products; An active technology pipeline focused on surgical-grade silicon nitride devices; Partnerships and licensing discussions with leading medical OEMs; SINTX’s Salt Lake City facility remains only FDA-registered and ISO 13485 certified, silicon nitride ceramic manufacturer. Improved Financial Position: $6.5M cash on hand as of March 31, nearly doubling from $3.6M at year-end; Recent $5M private placement in February 2025 supported strategic runway along with potential to raise an additional $5M from the exercise of warrants with an exercise price of $3.32 per share of common stock; Reduced operating cash burn from $2.7M in Q1 2024 to $1.3M in Q1 2025 due to cost optimization. Operational Streamlining: Sale of non-core subsidiary TA&T to Tethon Corporation; Workforce reduction and shut down of underperforming Armor subsidiary; Initiated negotiations to reduce long-term lease liabilities, particularly at the Armor facility. These actions are expected to further unlock capital for high-return growth projects. In Q2, the Company welcomed a reconstituted Board of Directors with new appointments across all Board committees, reinforcing corporate oversight. In parallel, the Company entered into new long-term employment agreements with CEO Eric Olson and CIO Gregg Honigblum SINTX is now strategically aligned around: Expanding the use of silicon nitride in medical and antipathogenic markets; Licensing and commercialization of proprietary technologies; Select asset divestitures and disciplined capital investment; Building long-term shareholder value through innovation and execution.